Spero Therapeutics Q3 EPS $(0.06) Misses $(0.03) Estimate, Sales $25.47M Beat $14.97M Estimate
Portfolio Pulse from bharat@benzinga.com
Spero Therapeutics (NASDAQ:SPRO) reported a Q3 EPS loss of $(0.06), which did not meet the expected $(0.03) estimate, marking a 100% miss. However, the company saw a significant increase in sales, reporting $25.47M against the $14.97M estimate, a 70.16% beat and a 1.17K% increase from the previous year's sales of $2.01M.
November 13, 2023 | 9:19 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Spero Therapeutics reported a larger than expected EPS loss but significantly exceeded sales estimates in Q3, indicating mixed financial performance.
The EPS miss may concern investors about profitability, potentially putting downward pressure on the stock. However, the substantial sales beat and year-over-year growth could offset this by suggesting strong revenue generation and market approval for Spero's products. The mixed results create uncertainty, hence a neutral score is given.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100